Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/IIa trial of TOL-2 for the treatment of myasthenia gravis

X
Trial Profile

A phase I/IIa trial of TOL-2 for the treatment of myasthenia gravis

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 23 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TOL 2 (Primary)
  • Indications Myasthenia gravis
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Toleranzia
  • Most Recent Events

    • 21 Aug 2023 According to a Toleranzia media release, the company announces that it has successfully completed the manufacturing steps of the GMP process for the TOL2 drug substance to be used in this trial. The GMP-grade drug product will subsequently be shipped to participating clinical centers.
    • 28 Mar 2022 According to a Toleranzia media release, the prospects of being able to start this study in the 2H2023 in accordance with the communicated schedule are strengthened, as the company has taken additional steps to secure access to the materials required to complete the scaleup of production and large scale manufacturing of TOL2; the Company has succeeded in finding an additional supplier and ordered, on behalf of its production partner 3P Biopharmaceuticals, all the purification material needed
    • 11 Nov 2021 According to a Toleranzia media release, the planned start of a first clinical study of its drug candidate TOL2 in patients with myasthenia gravis will be postponed until the second half of 2023 due to a continued global shortage of materials necessary for the purification of TOL2, which is also used in the prioritized manufacturing of covid-19 vaccines. The study was previously expected to be initiated before the end of 2022/23.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top